India Human Papillomavirus Vaccine Market to be Led by Multinational Pharmaceutical Companies Through 2029
The
increase in awareness about human papillomavirus vaccines among consumers is
expected to drive the India human papillomavirus vaccine market during the
forecast period.
According to the TechSci
Research report, “India Human Papillomavirus Vaccine Market - By
Region, Competition, Forecast, and Opportunities, 2029,” the human
papillomavirus vaccine market in India is anticipated to grow at an impressive
rate during the forecast period. This can be ascribed due to the
rising uptake of multi-valent human papillomavirus vaccines.
The India human papillomavirus
vaccine market witnessed a substantial increase in the last few years.
Multi-valent human papillomavirus vaccines are designed to protect against
several strains of human papillomavirus, compared to the bivalent vaccine that
protects against two human papillomavirus strains. The quadrivalent human papillomavirus vaccine and the nonvalent
human papillomavirus vaccine are two multi-valent human papillomavirus vaccines
that are currently available in India. These vaccines protect against more
strains of human papillomavirus, including those that are associated with a
higher risk of cervical cancer.
The uptake of multi-valent human papillomavirus vaccines in India has been
driven by several factors, including increased awareness of the risks
associated with cervical cancer, greater access to healthcare services, and the
introduction of newer and more effective vaccines. The uptake of
multi-valent human papillomavirus vaccines in this market is likely to continue
to increase and help in the growth of this market in the years to come. Key
trends in this market are emphasis on public-private partnerships and
public-private partnerships, formed to develop and distribute HPV vaccines in
India. This collaborative approach is expected to drive innovation, reduce
costs, and increase access to these products over the forecast period.
Governments, NGOs, and
healthcare organizations are working to increase access to HPV vaccines in
India, especially in rural areas where healthcare infrastructure is limited.
This includes various initiatives, such as mobile clinics, awareness campaigns,
and subsidized vaccine programs.
Although the market for the
human papillomavirus vaccine in India has been demonstrating an upward swing,
the reluctance among patients for vaccines is a massive roadblock in the
market’s otherwise positive growth trajectory. Some people are hesitant toward
vaccination due to concerns about safety, efficacy, and potential side effects.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC on
the “India Human Papillomavirus
Vaccine Market”
The
India human papillomavirus
vaccine market
can be segmented by valence, disease indication, distribution channel, and
region.
Based on disease indication, the market is segmented into cervical cancer, anal
cancer, vaginal cancer, penile cancer, vulvar cancer, and others. This
segment is expected to dominate the market during the forecast period as
cervical cancer is the most common human papillomavirus-related cancer in
India. The use of HPV vaccines has the potential to significantly reduce the
incidence of cervical cancer. Private healthcare providers are also offering
HPV vaccines in the country, which has further expanded access to these
vaccines and reduced the chance of getting cervical cancer.
Based on the distribution
channel, the market can be segmented into online markets and others. The
segment is expected to dominate during the forecast period as the online market
for human papillomavirus products and services is
growing rapidly in India. With the increasing use of digital technology,
patients are increasingly seeking information about their health online and are
using e-commerce platforms to purchase health products. This trend is also seen
in the human papillomavirus vaccine market, where patients are using
online platforms to purchase HPV vaccines, diagnostic tests, and
treatments.
Several online platforms
offer human papillomavirus products and services in India, including
e-pharmacies, online healthcare providers, and health and wellness portals.
These platforms offer a convenient and accessible way for patients to access HPV-related
products and services, particularly in remote or underserved areas where access
to healthcare may be limited.
Furthermore, the COVID-19 pandemic accelerated the growth of online markets in
the healthcare sector, especially the human papillomavirus vaccine market.
Patients are increasingly turning to online platforms to purchase healthcare
products and services, as social distancing measures and lockdowns have made it
difficult for patients to access traditional healthcare facilities.
Major
companies operating in the India Human Papillomavirus Market are:
- Bharat Biotech International Ltd.
- GlaxoSmithKline Pharmaceuticals Limited
- MSD Pharmaceuticals Private Limited
- Serum Institute of India Pvt. Ltd.
- HLL Lifecare Limited
- Panacea Biotec Ltd.
Recent
Development
- In 2020, MSD entered into a collaboration with Indian
Immunological Limited (IIL) to expand access to Gardasil 9, a multi-valent HPV
vaccine, in India. Under the collaboration, IIL will distribute the vaccine in
India.
- In 2019, Panacea Biotec
announced a collaboration with SII to develop and manufacture a quadrivalent
HPV vaccine. The vaccine is currently in clinical trials.
Download Free Sample Report
Customers
can also request 10% free customization on this report.
“The
India human papillomavirus vaccine market is expected to gain substantially from the
rising in cancer cases caused by Papillomavirus, such as vulva cancer, vagina
cancer, oropharynx cancer (back of throat including base of tongue and
tonsils). Furthermore, this market is in its nascent stage and is expected to
experience significant growth in the coming years. The inclusion
of human papillomavirus vaccines in the national immunization program
and the increasing awareness about cervical cancer prevention are likely to
play an important role in driving the growth in this market. Besides, rising
concerns about healthy lifestyles and increasing expenditure on health and
wellness are further expected to create lucrative opportunities for the
market’s growth over the forecast period,” said Mr. Karan Chechi, Research
Director at TechSci Research, a research-based global management consulting
firm.
India Human Papillomavirus
Vaccine Market By Valence (Bivalent,
Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal
Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel
(Hospitals & Clinics, Governmental & Non-Governmental Organizations,
Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunities, 2029 has evaluated the future growth potential of the
India human papillomavirus vaccine market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in the India human papillomavirus vaccine market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web:
https://www.techsciresearch.com